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Background. Streptococcus pneumoniae is a commonly found upper respiratory tract colonizer 
that can progress to more severe disease forms such as pneumonia. Interactions with respiratory 
viruses other than SARS-CoV-2 have been previously identified such that S. pneumoniae may 
sometimes enhance disease or occur as a secondary or co-infection. With the recent emergence 
of SARS-CoV-2 there is limited data available describing this specific pathogen relationship that 
could play a role in the breadth and severity of the pandemic.  
Methods. Inpatients and healthcare workers testing positive for SARS-CoV-2 March 2020-
August 2020 were tested for S. pneumoniae through saliva culture enrichment and RT-qPCR as 
well as urine antigen detection (UAD) assays. A multinomial multivariate model was used to 
examine the relationship between pneumococcal presence and COVID-19 outcomes. 
Results. Among 126 subjects enrolled, the median age was 62 years; 54.9% of subjects were 
male; 88.89% were inpatients; 23.5% had an ICU stay; and 13.5% were deceased. S. pneumoniae 
was detected in 17 subjects (13.5%) by any method, including 5 subjects (4.0%) by RT-qPCR 
and 12 subjects (13.6%) by UAD. Detection by UAD was highly associated with both moderate 
and severe COVID-19 disease while RT-qPCR detected states were not significantly predictive 
of such outcomes. Despite being associated with more severe outcomes, UAD positives 
represented 0/14 deaths within the study population.  
Conclusions. Pneumococcal presence, particularly in a disease state, may be associated with 
more serious outcomes of SARS-CoV-2 infections. Concerns surround high levels of antibiotic 
usage that may diminish the ability to detect pneumococci, particularly in culture. Future studies 
should be performed to better characterize the relationship between these two pathogens across 
all levels of disease status.  
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In the months following the identification of the SARS-CoV-2 virus as the cause of COVID-19 
and its establishment as a pandemic, much work has been done to understand the virus, course of 
infection, and establish treatment and prevention policies. Most cases of COVID-19 are mild to 
moderate in severity while some progress to severe outcomes including pneumonia, acute 
respiratory distress syndrome (ARDS), and death related to a variety of risk factors.1 
There remains limited characterization of SARS-CoV-2 interactions with both commensal 
bacteria and secondary infections.2 Advantageous bacterial pneumonias, particularly S. 
pneumoniae, are often responsible for much of the severity and mortality during viral 
epidemics.3-4 Prior research focuses primarily on respiratory viruses such as influenza and RSV 
where bacterial co-infection is relatively heterogenous in frequency and proportionality, yet S. 
pneumoniae is amongst the most common co-infecting pathogens.5 Early data suggests that the 
COVID-19 pandemic may show similar low-level co-infection patterns as well as more common 
occurrence in ICU patients suggesting a correlation with more severe clinical outcomes.6-7 Initial 
studies report any bacterial infection in approximately 6.9% of hospitalized and critically ill 
patients with COVID-19, as well as possible differences in bacterial composition than commonly 
described with other viral respiratory pathogens.8 
For some common respiratory pathogens, such as Influenza A, a lethal synergistic relationship 
has been described with pneumococci.9 Similarly, higher viral loads have been associated with 
more severe COVID-19 outcomes, but the interaction of bacterial co-infection on viral titers is 
not well characterized.10 In conjunction with the synergistic relationship described previously, 
there may be an increase in relative viral titer following pneumococcal challenge; however, as a 
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secondary infection this may not affect the peak viral load.11 Interestingly, an early SARS-CoV-2 
case study from Japan noted co-infection with S. pneumoniae that had the appearance of lobe-
level pathogen mutual exclusion such that S. pneumoniae was primarily found in the lower lungs 
and SARS-CoV-2 in the upper lobes.12 
To best address case outcomes and disease severity a more complete understanding of these 
microbial interactions is necessary. Upper respiratory tract carriage of S. pneumoniae is typically 
asymptomatic and can be a part of the normal flora; however, this colonization state can lead to 
disease states such as pneumonia or meningitis.13 Pneumococcal carriage and disease rates in the 
community are highest amongst children14 and the elderly,15 respectively, both groups of 
particular concern throughout the pandemic. Should S. pneumoniae carriage or progression to 
disease be associated with more severe COVID-19 outcomes these individuals may face an even 
greater risk. Furthermore, development of pneumococcal disease or even detection of carriage 
could lead to greater levels of broad-spectrum antibiotic use in patients that could exacerbate 
problems of antimicrobial resistance.16-17 Antimicrobial stewardship remains a complex and 
important factor in mitigating current and future populational infectious threats. 
Not only is there the potential for invasive, secondary infections from pneumococcus of concern 
in relation to SARS-CoV-2 infection, there could additionally be a relationship with common 
serotypes seen in carriage to enhanced disease severity.18-19 Contrarily, high carriage density has 
also been shown to be protective against respiratory syncytial virus (RSV) disease severity in 
infants related to the immune response.20 As of now, the within-host biological interactions of S. 
pneumoniae and SARS-CoV-2 that could influence disease progression and pathology have yet 
to be well characterized. Pneumococcal vaccines have been shown to have some indirect effect 
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on viral infections previously and could be highly influential should there be a relationship 
between SARS-CoV-2 and vaccine-type serotypes.21-22 Furthermore, this may be of particular 
importance with age and comorbidity-related morbidity and mortality risk in both pneumococcal 
and SARS-CoV-2 infections.23-24 
With the retrospective cohort of SARS-CoV-2 positive inpatients and healthcare workers 
available through the Yale IMPACT (IMplementing Public health Action against coronavirus 
CT) biorepository, we aim to identify the prevalence of pneumococcus within this population 
and explore its association with SARS-CoV-2. Based on pneumococcal interactions with other 
viral respiratory diseases there is reason for concern that pneumococcal presence could lead to 
more severe outcomes that must be explored within the specific context of SARS-CoV-2 
infection and its pandemic spread. The role of these potential relationships is important in 
considering public health response measures that could be used to mitigate both pneumococcal 




Study design. During March-August of 2020 de-identified saliva and urine samples were 
collected from SARS-CoV-2 positive inpatients and healthcare workers on COVID-19 units at 
Yale-New Haven Hospital as part of the IMPACT biorepository.25 Signed-informed consent was 
obtained from all study participants following Yale University HIC-approved protocol 
#2000027690. Demographic information was collected as part of biorepository efforts. Amongst 
the inpatients and healthcare workers identified and enrolled in the biorepository, 126 individuals 
who tested positive for SARS-CoV-2 had saliva samples remaining for testing in this study.  
Sample collection. Inpatient saliva self-collection was attempted every three days using the 
methods previously described.26 Likewise, healthcare workers were asked to collect saliva and 
nasopharyngeal swab samples as often as every three days for up to 84 days or testing positive 
for SARS-CoV-2. Samples were stored at room temperature and transported to the Yale School 
of Public Health within 5 hours of sample collection and tested for SARS-CoV-2 within 12 hours 
of sample collection. Urine collection was also attempted every three days from enrolled 
participants and stored at -80˚C until further processing. 
SARS-CoV-2 RNA detection in saliva. Nucleic acid was extracted from 300 μl of saliva using 
the MagMAX Viral/Pathogen Nucleic Acid Isolation kit (ThermoFisher Scientific) on the 
KingFisher DNA extraction robot (ThermoFisher Scientific) following a modified protocol.26 
Samples were classified as positive for SARS-CoV-2 when both N1 and N2 targets were 
detected with <40 CT by RT-qPCR. Where possible, 100 ul of the remaining sample volume was 
supplemented with 20 µl brain heart infusion (BHI) supplemented with 50% glycerol and stored 
at -80˚C for further analysis.25 
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Culture enrichment and detection of pneumococcal carriage using the molecular method. 
For all COVID-19 inpatients and for healthcare workers with at least one SARS-CoV-2 positive 
test, by any sample type, remaining saliva samples were tested for pneumococcal carriage. Both 
raw and BHI/10% glycerol supplemented saliva samples were first culture enriched with 100 µl 
on gentamicin (10%) supplemented blood agar plates. 27 Cultures were incubated overnight after 
which all growth was harvested into 2100 µl of BHI supplemented with 10% glycerol and stored 
at -80˚C. Pneumococcal detection was performed by DNA extraction of 200 µl of each sample 
using the MagMAX Ultra Viral/Pathogen Nucleic Acid Isolation kit (ThermoFisher Scientific) 
on the KingFisher DNA extraction robot (ThermoFisher Scientific) following manufacturer’s 
protocol. Samples were classified as positive when both piaB28-29 and lytA30 targets were <40 CT 
by RT-qPCR. 
Urine antigen detection (UAD). Urine samples were thawed at room temperature and aliquoted 
into PIPES buffer. Aliquots were re-frozen at -80˚C in preparation for batch shipping on dry ice 
to the reference laboratory of Pfizer Vaccine Research (Pearl River, NY) for testing31. Upon 
receipt, samples were stored at -80˚C until batched urine antigen testing could be performed 
using the serotype-specific UAD and/or BinaxNOW tests according to manufacturer’s protocol. 
Statistical analysis. Differences in demographic data between pneumococcal status groups were 
tested using analysis of variance F-test (continuous variable) or χ2 test (categorical variable). 
Multivariate and multinomial logistic regression analyses were used to evaluate the association 
SARS-CoV-2 infection outcome levels with pneumococcal status. The outcome variable was 
trichotomous for whether an individual was mild/asymptomatic, moderate, and severe disease as 
defined by clinical scoring using a custom disease severity scale.37 The model was pared down 
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according to AIC scores and odds ratio confidence intervals between versions. Covariates 
included in the final version were pneumococcal status (negative, positive by RT-qPCR, 
indeterminant – lytA by RT-qPCR, positive or indeterminant by UAD), age, sex, BMI, and race. 
Model coefficients and confidence intervals were exponentiated to transform into odds. 
Estimates were considered statistically significant at p<0.05. All statistical analyses were 
performed in RStudio v1.2.133535, using R v3.6.1.36 
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Results & Discussion 
Pneumococcal Detection 
A total of 235 saliva samples from 126 SARS-CoV-2 positive individuals, comprised of 14 
healthcare workers (HCW) and 112 inpatients (INP), were culture enriched and tested by RT-
qPCR for S. pneumoniae. Of these, eight samples, representing five individuals, tested positive 
for both bacterial targets suggesting a pneumococcal carriage rate of 4.0% amongst those with 
SARS-CoV-2. A further 11 individuals tested positive for lytA alone suggesting possible 
streptococcal carriage of 12.7%. Additionally, 159 inpatients were tested for S. pneumoniae by 
Urine Antigen Detection (UAD), 88 of whom were also tested by saliva. Of these, 15 individuals 
(9.4%) tested positive for at least one pneumococcal polysaccharide antigen, 12 of whom were 
also tested by saliva (13.6%). Furthermore, three individuals were indeterminant by UAD with 
one simultaneously tested by saliva.  
The outcomes of both culture enrichment/RT-qPCR and UAD tests were used to classify 
pneumococcus status (Table 1) in order to further explore the relationships between these 
samples. Amongst the different pneumococcal statuses there does not appear to be any 
association with SARS-CoV-2 N1 or N2 cycle threshold (CT) values in saliva (Figure 1). There 
is no apparent correlation between N1 and lytA  (R=-0.363) or piaB (0.194) CT values, when both 
detected, suggesting that viral load may not affect pneumococcal abundance. Likewise, all such 
true pneumococci were detectable in the first saliva samples collected indicating pre-existing 
carriage with latest detection occurring in early May. UAD positives, however, occurred 
throughout the course of infection suggesting possible acquisition during the course of stay with 
detection spread throughout most of the study period. Incidence of S. pneumoniae by UAD 
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(13.6%) is highly similar to levels of detection seen amongst older adults with general 
community-acquired pneumonias seen throughout the U.S. previously35 suggesting that 
secondary infections in COVID-19 patients may be on par with what has previously been 
described. 
Table 1. Classification of pneumococcus status. 
 
Notably, there was no concordance for pneumococcal detection between positives and 
indeterminants within individuals tested by both methods. This lack of concordance could reflect 
detection of two separate types of pneumococcal events with differing implications for overall 
outcomes and may be explained in part by the testing methods themselves. UAD is designed to 
particularly detect pneumococcal pneumonia rather than carriage,31 establishing this 
classification status as a secondary infection compared to the culture enrichment based statuses 
that suggest carriage. Additionally, culture enrichment steps limit detection to living bacteria in 
saliva36 and does not account for disruption of S. pneumoniae colonization, such as by antibiotic 
usage, leading to the presence of killed bacteria that could be detected by DNA extraction alone. 
Evidence of mutually exclusive lung pathology within co-infection12 states with S. pneumoniae 
primarily residing in the lower lobes of the lung supports the idea that saliva-based culture 
enrichment may not be able to as readily identify pneumococcal pneumonias due to lack of 
bacterial colonization in the upper respiratory tract. Future studies with both greater sample 
Pneumococcus Status Definition 
0 Not detected by any measure 
1 RT-qPCR: lytA CT  <40; piaB  CT  <40 
2 RT-qPCR: lytA  CT  <40; piaB  CT  >40 or not detected 
3 UAD positive or indeterminant 
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collection volumes, preferably 1.5mL or greater, and greater participant enrollment could 
combine all of these techniques to better identify and tease apart these coinfections. 
 
Figure 1. SARS-CoV-2 N1 in comparison to both SARS-CoV-2 N2 and S. pneumoniae lytA and piaB CT values broken 
down by pneumococcal status. A positive trend can be seen between N1 and N2 CT values as expected with consistent within-
host viral load. Pneumococcal gene targets can be seen throughout a spectrum of SARS-CoV-2  detection levels and appear 
largely independent from viral load. 
Overall, pneumococcal carriage estimates (4.0%) within this study population are low relative to 
rates reported throughout the literature for non-elderly and elderly adults alike, but particularly in 
older adults with influenza-like illnesses which this study population most closely reflects.27,37 It 
is likely that a number of factors are contributing to this discrepancy apart from SARS-CoV-2 
infection. With the majority of participants enrolled due to COVID-19 inpatient status, it is 
possible that many may have been provided antibiotics upon admission or during their stay. 
Additionally, pandemic response measures such as social distancing and masking minimized 
contact between individuals that may have driven transmission and colonization, particularly 
between grandchildren and their grandparents.38 Furthermore, related to the timing of the 
pandemic itself, samples were collected March-August 2020 while most studies estimating 
pneumococcal carriage are typically performed during the peak respiratory pathogen seasons of 




Key demographical differences exist amongst the pneumococcal status groups (Table 2). 
Amongst the four primary bacterial classifications detailed, significant differences were 
identified in the categories of family size and race/ethnicity (α=0.05) by ANOVA or χ2. The 
strep/pneumococcal carriage states participants were, on average, younger and had more family 
members living in their home possibly indicating a parental role or at least children in the home. 
Individuals spending more time around children may help explain their carrier state apart from 
SARS-CoV-2 infection.37 Conversely, in these factors UAD positive individuals look much more 
like those without any form of pneumococcal detection supporting UAD as a possible secondary 
infection acquired in the hospital or community rather than a form of carriage. Additionally, 
UAD classification shows the most distinct racial grouping compared to all of the other detection 
statuses. This subset is predominately black while the others are mostly white, although the 
pneumococcal carriage (lytA and piaB positive) group was evenly distributed along racial lines. 
Based on summary demographics alone it is difficult to determine the relationship between 
pneumococcal pneumonia, severity of COVID-19, and race, but this raises important questions 
on the disproportionate burden of disease and health equity. Furthermore, the small sample size 
of study participants and individual pneumococcal statuses increases challenges in identifying 
whether these differences are clinically meaningful or a product of sampling biases.  
Pneumococcal status as a predictor of SARS-CoV-2 outcomes 
The “case status” variable was selected as a primary outcome measure due to completeness of 
data and more consistent classification of SARS-CoV-2 outcomes than deaths or admission to 
ICU. This measure appears to have a relationship with pneumococcus status (Figure 2), UAD 
positives being of particular note in severe classification compared to other bacterial states. 
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Interestingly, none of those who were UAD positive died despite being primarily comprised of 
severe cases while 11/31 (35.5%) of non-pneumococcal severe cases are known to be deceased. 
At this time it is difficult to say with certainty why such a difference in case fatality may be 
occurring. One possible explanation may relate to available courses of treatment and 
classification systems such that any form of pneumonia is more readily classified as severe 
disease while a secondary, pneumococcal pneumonia may be more treatable than a primary 
COVID-19 pneumonia. While some patients will progress to UAD positive pneumococcal 
pneumonia state, many will already be on or can have near-immediate antibiotic starts. 
 
 
Figure 2. Outcome Measures of COVID-19 infection categorized by pneumococcal status. UAD positive individuals are 
disproportionally categorized as severe disease, particularly in comparison to the other pneumococcal statuses. Despite this, 
deceased individuals primarily have no detection of S. pneumoniae and no UAD positives died while hospitalized for COVID-19. 
In order to broadly examine the role that pneumococcal status may play in clinical outcomes, 
broken down as asymptomatic/mild, moderate, and severe disease, a multivariate multinomial 
model was developed. Additional covariates were included in order to adjust for other factors 
that may influence both COVID-19 outcomes and pneumococcal status. After adjustment –  
increasing age, male sex, and UAD positive status suggest an increased risk of both moderate 
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Table 2. Demographics by pneumococcal status. 
* Numbers may not sum to totals due to missing data, and column percentages may not sum to 100% due to rounding. 
† P-value for analysis of variance F-test (continuous variable) or χ2 test (categorical variable) between individual pneumococcal levels, 
not including “Any Detection”. 
 
Characteristic No Pneumococcal Detection (n = 97) 
lytA & piaB 
Positive 
(n = 5) 
lytA 
Positive 
(n = 11) 




(n = 29) p
† 
Age (years), mean ± SD 58.7 ± 18.3 54.8 ± 20.4 46.1 ± 15.3 59.2± 21.1 53.5 ± 19.3 0.190 
BMI, mean ± SD 31.9 ± 7.9 31.0 ± 11.7 29.0 ± 5.8 29.0 ± 7.3 29.3 ± 7.2 0.500 
Family Size, mean ± 
SD 1.1 ± 1.5 3.8 ± 4.5 2.1 ± 1.6 0.7 ± 1.0 1.7 ± 2.3 0.005 
Sex       
     Female 42 (45.2) 3 (60.0) 3 (27.3) 7 (53.8) 13 (44.8) 0.520 
     Male 51 (54.8) 2 (40.0) 8 (72.7) 6 (46.3) 16 (55.2)  
Patient Type, n (%)      0.172 
     HCW 10 (10.3) 1 (20.0) 3 (27.3) 0 (0.0) 4 (13.8)  
     INP 87 (89.7) 4 (80.0) 8 (72.7) 13(100.0) 25 (86.2)  
Admitted to ICU, n (%)      0.263 
     No 58 (76.3) 3 (75.0) 8 (100.0) 6 (60.0) 17 (77.3)  
     Yes 18 (23.7) 1 (25.0) 0 (0.0) 4 (40.0) 5 (22.7)  
Patient Status, n (%)      0.433 
     Living 69 (84.1) 3 (100.0) 6 (85.7) 12 (100.0) 21 (95.5)  
     Deceased 13 (15.9) 0 (0.0) 1 (14.3) 0 (0.0) 1 (4.5)  
Case Status, n (%)      0.072 
     Asymptomatic/Mild 15 (19.5) 2 (50.0) 4 (36.4) 0 (0.0) 6 (22.2)  
     Moderate 31 (40.3) 1 (25.0) 5 (45.5) 3 (25.0) 9 (33.3)  
     Severe 31 (40.3) 1 (25.0) 2 (18.2) 9 (75.0) 12 (44.4)  
Race/Ethnicity, n (%)      0.003 
     Non-Hispanic white 38 (50.7) 1 (33.3) 7 (70.0) 1 (10.0) 9 (39.1)  
     Non-Hispanic black  23 (30.7) 1 (33.3) 0 (0.0) 9 (90.0) 10 (43.5)  
     Hispanic 14 (18.7) 1 (33.3) 3 (30.0) 0 (0.0) 4 (17.4)  
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and severe disease with odds ratios of 1.13/1.16, 11.35/30.68, and 2926.91/8252.83 
(moderate/severe), respectively (Tables 3&4). Carriage-based pneumococcal statuses were not 
predictive of clinical severity level in this model. To this extent, further questions can be raised 
as to whether a UAD positive status is predictive of case status or if the exact opposite is true. 
More severe cases of COVID-19 may be more likely to develop a secondary pneumococcal 
pneumonia due to existing disease pathology. The particularities of this relationship will require 
more in-depth future study in both epidemiological and molecular mechanisms. 
With such sparse data overall, it is difficult to confidently describe the effects of pneumococcal 
status on COVID-19 outcomes. A variety of issues arise with running the model in its current 
form, but of primary concern is the data stratification of already small sample sizes. For example, 
the odds ratios of UAD positive status are much higher than one would expect in part due to no 
individuals in the mild /asymptomatic reference outcome. Ideally, more individuals of all 
pneumococcal classifications would be included in this study to more completely assess the role 
of S. pneumoniae in the SARS-CoV-2 pandemic. 
Table 3. Odds ratios from multinomial regression, “Moderate”. 
 
Characteristic Adjusted OR (95% CI) p 
Pneumococcus Status   
     No Detection 1.00 --- 
     lytA & piaB 0.98 (0.00, 287.72) 0.995 
     lytA 0.94 (0.05, 16.71) 0.967 
     UAD Positive 2926.91 (1279.16, 6697.22) <0.001 
Age 1.13 (1.05, 1.21) <0.001 
Sex   
     Female 1.00 --- 
     Male 11.35 (1.46, 88.38) 0.020 
BMI 1.04 (0.89, 1.22) 0.608 
Race   
     Non-Hispanic white 1.00 --- 
     Non-Hispanic black 3.47 (0.14, 88.51) 0.452 
     Hispanic 7.16 (0.61, 83.47) 0.116 
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Table 4. Odds ratios from multinomial regress, “Severe”. 
 
Characteristic Adjusted OR (95% CI) p 
Pneumococcus Status   
     No Detection 1.00 --- 
     lytA & piaB 0.47 (0.00, 342.06) 0.824 
     lytA 0.17 (0.00, 6.34) 0.340 
     UAD Positive 8252.83 (3607.77, 18878.46) <0.001 
Age 1.16 (1.07, 1.25) <0.001 
Sex   
     Female 1.00 --- 
     Male 30.68 (3.30, 285.04) 0.003 
BMI 1.12 (0.95, 1.32) 0.181 
Race   
     Non-Hispanic white 1.00 --- 
     Non-Hispanic black 7.72 (0.29, 208.24) 0.224 
     Hispanic 15.15 (1.03, 223.89) 0.048 
 
Serotypes and pneumococcal vaccines 
While serotyping could not be performed for the culture enriched samples due to time and 
resource constraints, 8/12 of the UAD positives samples, excluding the one indeterminant, were 
run on the serotype-specific UAD test. Of these eight samples, three were identified as serotypes 
covered in the pneumococcal conjugate vaccine (PCV13) and all eight are covered in the 
pneumococcal polysaccharide vaccine, (PPSV23). Future explorations should consider 
pneumococcal vaccination status when aiming to look at serotype-specific patterns and effects. It 
is unlikely that most individuals in this study would have received either vaccine due to timing of 
vaccine introductions and age-based recommendations.39 Approximately 33% of individuals 
included in the study are estimated to have qualified for vaccination either in childhood or older 
adulthood, with a slightly higher proportion amongst those who were UAD positive. 
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Antibiotic resistance and stewardship 
Of the utmost importance in collecting accurate data on pneumococcal status is antibiotic usage, 
particularly for inpatients. These data were not available without extensive chart review through 
the biorepository; however, studies suggest that general use in inpatients may be upwards of 
70%.16 There is anecdotal evidence of this within the study population (S. Farhadian, personal 
communication, February 1, 2021) and in a number of samples that showed little to no bacterial 
growth when cultured despite adequate sample volume and incubation time. Culture enrichment 
should produce a solid lawn of bacterial growth due to the polymicrobial nature of saliva. 
Minimal growth by these methods indicates a large disruption of the bacterial flora, likely due to 
antibiotic use. Should such a high level of antibiotic usage be the case amongst COVID-19 
patients enrolled then our estimates of pneumococcal prevalence are likely minimized and do not 
allow for adequate stratification of individuals that introduces biases to the analysis of 
implications for disease severity. These data will be necessary to understanding the relationship 
between these two pathogens in disease progression and pathology. Most of the literature 
available discusses S. pneumoniae with other respiratory viruses which present good initial 
comparisons but fail to address the intricacies of SARS-CoV-2 specifically. Determining 
prevalence of co-infection, of any type, can justify further studies into biological mechanisms 
and relationships, so it is vital to tease apart whether this is low because of preemptive antibiotic 
usage rather than pathogen-pathogen interactions within an individual. 
Even in the midst of a pandemic that continues to rage on, public health and medical officials 
must remain vigilant in maintaining antibiotic stewardship. Heavy antibiotic use in COVID-19 
wards may be warranted if secondary bacterial infections, pneumococcal or otherwise, are 
common. However, if rates are lower or secondary infection can be identified easily and early on 
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then proactive prescribing should be discontinued, particularly in lower risk groups. With rising 
antibiotic resistance across many bacteria and without indication of necessity in patients, this 
outdated practice seemingly makes broader public health problems worse without actually 
improving patient outcomes.  
Future Directions 
One of the major limitations of this study is small sample size and incomplete demographic and 
medical data. With the extensiveness of the pandemic, future studies could be expanded to 
include more individuals of varying disease severities and demographic backgrounds with more 
complete sample and data collection. This could be done both retrospectively through chart 
reviews and analysis of previously stored samples or prospectively with new cases and data 
collection. Future studies should strive to have the most complete data possible on 
demographics, medical history, and treatments used for all enrolled individuals. Increasing 
longitudinal saliva and urine collection during both inpatient and outpatient stay to monitor both 
existing and newly acquired carriage as well as secondary infection throughout the duration of 
disease could help inform important questions on the roles of these different types of 
pneumococcal states. The methods and analyses detailed throughout this paper could function as 
a basic starting point for this sort of ongoing development. Furthermore, a comprehensive 
longitudinal surveillance study for both the general community and inpatients would best inform 
the dynamics and interconnectedness of SARS-CoV-2 and S. pneumoniae as well as other 
respiratory pathogens. A large research institution with corresponding healthcare system may be 
able to work together to tack this onto COVID-19 surveillance programs to sustainable serve the 




In conclusion, a low prevalence of pneumococcal carriage was identified amongst SARS-CoV-2 
positive individuals when molecular methods where used. A higher prevalence of pneumococcal 
pneumonia was seen within the same population and without overlap. Furthermore, this 
pneumococcal disease state was associated with more severe cases and outcomes of COVID-19, 
while carriage did not increase these odds. Detection of pneumococci may be biased by inpatient 
treatments, seasonal timing, and public health measures that could mask true pathological 
relationships. High levels of antibiotic use may be a contributing factor to this masking which 
could have implications for antimicrobial stewardship and the growing problem of drug 
resistance. Future studies should aim to more deeply and longitudinally explore these dynamics 
in order to better define the relationship between these pathogens and implement both clinical 
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